Home > Products > Antibodies > Biosimilars

Research Grade Coltuximab (HB996016)

Price(USD): $
Spec:
  • 100ug
  • 1mg
Number:
Contact us
  • Overview
  • Images
  • References
  • Datasheet
Overview
Catalog No.HB996016
DescriptionColtuximab ravtansine (SAR3419) is an antibody-drug conjugate (ADC) targeting CD19 created by conjugating a derivative of the potent microtubule-acting cytotoxic agent, maytansine, to a version of the anti-CD19 antibody, anti-B4, that was humanized as an IgG1 by variable domain resurfacing. Four different linker-maytansinoid constructs were synthesized (average ∼3.5 maytansinoids/antibody for each) to evaluate the impact of linker-payload design on the activity of the maytansinoid-ADCs targeting CD19. Anti-CD19 humanized monoclonal antibody conjugated to DM4.
Species reactivityHuman
ApplicationsResearch Grade Biosimilar
Host speciesChimeric
IsotypeIgG1-kappa
Expression systemMammalian Cells
SpeciesHuman
ClonalityMonoclonal
TargetCD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4
Concentration1 mg/ml
Endotoxin levelPlease contact with the lab for this information.
Purity>95% as determined by SDS-PAGE.
PurificationProtein A/G purified from cell culture supernatant.
AccessionP15391
FormLiquid
Storage buffer0.01M PBS, pH 7.4.
Stability and StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternate NamesSAR3419, CAS: 1269764-99-9
NoteFor research use only. Not suitable for clinical or therapeutic use.
Images
  • Bioactivity

    SEC-HPLC detection for Research Grade Coltuximab.

References

Recommendation